We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Biogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of its blockbuster spinal muscular atrophy (SMA) drug Spinraza. This new ...

regulatory and commercial milestones, as well as royalties on any future sales. BTK has become something of a hot target in MS research, and Biogen's deal follows Sanofi's $3.7 billion takeover of ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful ... doing nothing to quell debate about its commercial prospects. The latest study – called CORAL ...

Biogen CEO Christopher Viehbacher wrote that his company’s experience selling nervous system drugs would “enable more streamlined operations and efficient commercial execution” around ...

The company and Biogen continue to work to grow Zurzuvae in PPD as well. Sage slashes half its workforce in rejig targeting Zulresso commercial team Sage’s stock closed Friday at a price of $5. ...

the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may ...

Citi analyst Geoff Meacham lowered the firm’s price target on Biogen (BIIB) to $160 from $190 and keeps ... but growth expectations appear beatable with a focus on commercial execution, the analyst ...

That’s the message Biogen chief executive Chris Viehbacher ... we face a lot of scientific and commercial risk, but we’re now facing a lot more policy risk, particularly now with the ...

the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may ...